Key terms

About RPTX

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest RPTX news

Apr 21 9:35am ET Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuation by TipRanks Apr 19 8:31am ET Repare Therapeutics reinstated with a Buy from Accumulate at Bloom Burton by TipRanks Mar 08 6:35am ET Buy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts Ahead by TipRanks Feb 28 4:30pm ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Feb 28 4:20pm ET SHAREHOLDER ALERT: Potential Recovery for Repare Therapeutics Inc. (RPTX) Investors by TipRanks Feb 28 2:50pm ET Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Repare Therapeutics (RPTX) by TipRanks Feb 28 11:37am ET Repare Therapeutics Reports Promising 2023 Progress by TipRanks Feb 28 7:13am ET Repare Therapeutics reports Q4 EPS (67c), consensus (46c) by TipRanks Feb 21 6:25am ET Strong Buy: Repare Therapeutics’ Promising Clinical Outcomes in Cancer Therapy by TipRanks Feb 15 7:45am ET Repare Therapeutics doses first patient in LIONS clinical trial by TipRanks Feb 14 6:11am ET Repare Therapeutics price target lowered to $10 from $25 at H.C. Wainwright by TipRanks Feb 13 7:37am ET Repare Therapeutics (RPTX) Gets a Buy from Stifel Nicolaus by TipRanks Feb 13 7:36am ET Piper Sandler Keeps Their Buy Rating on Repare Therapeutics (RPTX) by TipRanks Feb 13 5:13am ET Buy Rating on Repare Therapeutics: Solid Financials and Promising Oncology Pipeline Despite Roche Setback by TipRanks Feb 12 5:04pm ET Repare Therapeutics Regains Rights, Ends Roche Agreement by TipRanks Feb 12 4:06pm ET Repare Therapeutics to regain global rights to Camonsertib by TipRanks Jan 26 6:20am ET Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Repare Therapeutics (RPTX) by TipRanks Jan 26 4:22am ET Repare Therapeutics Receives Milestone Payment from Roche by TipRanks Jan 25 10:44am ET Capital One says buy these six biotech stocks for 2024 by TipRanks Jan 25 10:44am ET Capital One says buy these six biotech stocks for 2024 by TipRanks Jan 25 9:03am ET Capital One reveals top six biotech picks for 2024 by TipRanks Jan 25 7:12am ET Repare Therapeutics earns $40M milestone payment from Roche for TAPISTRY trial by TipRanks

No recent press releases are available for RPTX

RPTX Financials

1-year income & revenue

Key terms

RPTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

RPTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

The logo of Swiss bank UBS is seen at the company's headquarters in Zurich, Switzerland February 10, 2015. REUTERS/Arnd Wiegmann/File Photo
Arnd Wiegmann/Reuters
Switzerland says UBS may need more cash. The bank is fuming
Jamie Dimon, Chairman and Chief Executive officer (CEO) of JPMorgan Chase & Co. (JPM) speaks to the Economic Club of New York in Manhattan in New York City, U.S., April 23, 2024. REUTERS/Mike Segar
Mike Segar/Reuters
Jamie Dimon fears for the future of the free world and US debt
A bubble tea store operated by Sichuan Baicha Baidao in Shanghai, China, on April 23, 2024.
Raul Ariano/Bloomberg/Getty Images
Is the tea bubble bursting? ChaPanda shares plunge in Hong Kong IPO
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Can markets make a comeback? That depends on tech earnings